[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fuvQaeDVntWkRpcbe6Xjmazidv_-hqXefomYEZgWfhFo":8,"$fUB8aXjd4HPxb83ls2nPQljxED5LSK0gH3eoEqvC26yc":54,"$fKt6n9OTVDooSfXi3Oqy2Jv02RI5GNp0zvsZhT1Y5CVo":58},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":53},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":4,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":27,"seoTitle":22,"seoKeywords":28,"seoDescription":29,"shelvesTime":30,"version":31,"menus":32,"menuId":34,"type":41,"quality":52,"commentCount":21,"isComment":41},68938,867252,[],"https://ystcdn.venuertc.com/medical/ystApp/3PMFog9SJLbtP3VML2xGXUy2tMSMprgU.png","曾珊珊","潍坊市益都中心医院","血液内科","住院医师",447,0,"急性髓系白血病治疗指南：理解维奈克拉与阿糖胞苷的作用 💊","","https://ystcdn.venuertc.com/venue/AI/e377b799-08c9-4acf-b547-9550f9f79d62.jpg","\u003C!-- 急性髓系白血病治疗指南：理解维奈克拉与阿糖胞苷的作用 -->\n\u003Cdiv class=\"aml-material-root\">\n  \u003Ch1 id=\"material_title\" class=\"aml-material-title\">急性髓系白血病治疗指南：理解维奈克拉与阿糖胞苷的作用 💊\u003C/h1>\n  \u003Cdiv class=\"aml-material-section aml-material-section-intro\">\n    \u003Cp>说到维奈克拉和阿糖胞苷，这两种药物其实在特定治疗方案中有着不可替代的作用。维奈克拉属于靶向抗肿瘤药，阿糖胞苷则是经典的化疗药物。对于需要进行联合治疗的患者，掌握6个关键用药细节，能够提升药效、减少风险。下面我们就帮你弄清这些药品的核心使用要点。\u003C/p>\n  \u003C/div>\n\n  \u003C!-- 剂型及成分详细解析 -->\n  \u003Cdiv class=\"aml-material-section aml-material-bg\" style=\"background: linear-gradient(90deg, #f9f9fc 0%, #eef5fc 100%);\">\n    \u003Ch2 class=\"aml-material-subtitle\">1. 剂型与成分分析 🧪\u003C/h2>\n    \u003Cul class=\"aml-material-list\">\n      \u003Cli>\n        \u003Cstrong>维奈克拉：\u003C/strong>主要以片剂（100mg/片、10mg/片等规格）为主，有时也见到胶囊剂型。成分名称为venetoclax。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>阿糖胞苷：\u003C/strong>常见剂型为注射液（液体瓶装，规格有100mg、500mg等），成分名cytarabine。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>正确做法：\u003C/strong>维奈克拉片需整片吞服，不可咀嚼或掰开；阿糖胞苷注射液则需经专业人员静脉滴注或皮下注射，家庭自用不推荐。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\n  \u003C!-- 药品作用机制单独说明 -->\n  \u003Cdiv class=\"aml-material-section aml-material-bg\" style=\"background: linear-gradient(90deg, #eefdff 0%, #f5f8fc 100%);\">\n    \u003Ch2 class=\"aml-material-subtitle\">2. 作用机制简述 🧭\u003C/h2>\n    \u003Cul class=\"aml-material-list\">\n      \u003Cli>\n        \u003Cstrong>维奈克拉：\u003C/strong>通过抑制BCL-2蛋白，使异常细胞失去保护机制，从而促进细胞凋亡（\u003Cem>Roberts et al., 2018\u003C/em>）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>阿糖胞苷：\u003C/strong>能掺入细胞DNA，阻断基因复制，导致细胞死亡（\u003Cem>Döhner et al., 2022\u003C/em>）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>正确做法：\u003C/strong>理解药品机制虽有助于知晓其联合价值，但实际用药时要依照医师建议，严格遵循剂量和疗程。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\n  \u003C!-- 用法用量，不重复药理作用 -->\n  \u003Cdiv class=\"aml-material-section aml-material-bg\" style=\"background: linear-gradient(90deg, #f9f5e9 0%, #f5fcf9 100%);\">\n    \u003Ch2 class=\"aml-material-subtitle\">3. 用法用量关键细节⏰\u003C/h2>\n    \u003Cul class=\"aml-material-list\">\n      \u003Cli>\n        \u003Cstrong>维奈克拉：\u003C/strong>通常每日一次，餐饭前后均可，但建议于每日同一时间服用。启动剂量需逐渐递增（如10mg-50mg-100mg……），避免起始剂量过高。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>阿糖胞苷：\u003C/strong>按体表面积调整剂量，给药周期（如每天一次或连用多天）视具体方案而定，须由专业医护人员操作。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>案例参考：\u003C/strong>一位男性患者在联合用药期间，维奈克拉启动阶段采用递增方案，未出现剂量骤增引发的不良反应。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>正确做法：\u003C/strong>维奈克拉递增阶段绝不能自作主张缩短，每次加量必须严格对照医嘱。阿糖胞苷需专科注射，不能自行调整注射剂量、间隔。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\n  \u003C!-- 药物相互作用 -->\n  \u003Cdiv class=\"aml-material-section aml-material-bg\" style=\"background: linear-gradient(90deg, #fff7fb 0%, #f3faff 100%);\">\n    \u003Ch2 class=\"aml-material-subtitle\">4. 药物相互作用⚠️\u003C/h2>\n    \u003Cul class=\"aml-material-list\">\n      \u003Cli>\n        \u003Cstrong>维奈克拉：\u003C/strong>遇到强效CYP3A抑制剂（如酮康唑、克拉霉素）、葡萄柚汁时药物血浓度显著上升，易产生严重毒性（\u003Cem>DiNardo et al., 2020\u003C/em>）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>阿糖胞苷：\u003C/strong>和其他细胞毒性药同时使用时会相互增强副作用，特别需警惕骨髓抑制类药物。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>正确做法：\u003C/strong>服用维奈克拉期间，避免摄入葡萄柚及相关抑制剂药物。阿糖胞苷周期内禁止随意增加联合化疗药品，必须全程告知医生已用药品清单。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>案例提示：\u003C/strong>临床有患者在合用酮康唑后明显出现维奈克拉副作用，后调整用药方案方缓解。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\n  \u003C!-- 特殊人群用药调整 -->\n  \u003Cdiv class=\"aml-material-section aml-material-bg\" style=\"background: linear-gradient(90deg, #f6fff2 0%, #f4f8ff 100%);\">\n    \u003Ch2 class=\"aml-material-subtitle\">5. 特殊人群用药须知 👴👩‍🦳\u003C/h2>\n    \u003Cul class=\"aml-material-list\">\n      \u003Cli>\n        \u003Cstrong>老年患者：\u003C/strong>多伴随肾功能减退，需调整维奈克拉起始剂量及递增节奏，阿糖胞苷也应根据肾功能降低剂量。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>肝肾功能损害者：\u003C/strong>维奈克拉在严重肝损者体内清除减慢，剂量须下调。阿糖胞苷肾功能障碍时须慎用甚至停药。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>孕妇和哺乳期：\u003C/strong>维奈克拉、阿糖胞苷均禁用，因有致畸、致遗传毒性的风险。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>儿童：\u003C/strong>维奈克拉使用需按体重换算并密切监控不良反应，阿糖胞苷儿童用量需严格对照方案，不可随意调整。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>正确做法：\u003C/strong>特殊人群务必在专科医生指导下调整剂量，无自我加减药的空间。孕妇哺乳期需提前告知医生，并彻底避免接触相关药品。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\n  \u003C!-- 常见不良反应 -->\n  \u003Cdiv class=\"aml-material-section aml-material-bg\" style=\"background: linear-gradient(90deg, #fdf9e9 0%, #e6fdf6 100%);\">\n    \u003Ch2 class=\"aml-material-subtitle\">6. 常见不良反应及处理🩺\u003C/h2>\n    \u003Cul class=\"aml-material-list\">\n      \u003Cli>\n        \u003Cstrong>维奈克拉：\u003C/strong>最常见为白细胞急剧下降（14-30%）、消化道不适、疲乏。此外，罕见肿瘤溶解综合征，严重时需停药住院。（\u003Cem>DiNardo et al., 2020\u003C/em>）\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>阿糖胞苷：\u003C/strong>可以引发恶心、呕吐、骨髓抑制（例如血小板减少），长期使用易出现中枢神经紊乱或肝功能异常。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>出现不良反应正确做法：\u003C/strong>若发生持续腹泻、极度乏力、出血征象，务必立即就医，不得延误。肿瘤溶解风险期段（维奈克拉启动初期）要密切检测实验室数据，发现急剧变化应中断用药并求医。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>案例采集：\u003C/strong>一位患者在阿糖胞苷化疗后，血小板骤降至28×10⁹/L，及时调整支持治疗使血象恢复。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\n  \u003C!-- 储存与有效期 -->\n  \u003Cdiv class=\"aml-material-section aml-material-bg\" style=\"background: linear-gradient(90deg, #f5fbfc 0%, #fcf8ec 100%);\">\n    \u003Ch2 class=\"aml-material-subtitle\">7. 储存条件与有效期⏳\u003C/h2>\n    \u003Cul class=\"aml-material-list\">\n      \u003Cli>\n        \u003Cstrong>维奈克拉：\u003C/strong>应存放于干燥、阴凉处，温度不大于30°C，开瓶后建议4周内用完，避免高温潮湿环境。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>阿糖胞苷：\u003C/strong>未开封注射液需2-8°C冷藏，调配后应即刻使用，剩余药品48小时内必须丢弃，不得二次使用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>过期处理：\u003C/strong>绝对禁止服用过期维奈克拉片或用未冷藏的阿糖胞苷溶液。多余药品应带到药房或医疗机构回收，不随意丢弃。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\n  \u003C!-- 漏服与过量应对 -->\n  \u003Cdiv class=\"aml-material-section aml-material-bg\" style=\"background: linear-gradient(90deg, #fcf7fc 0%, #f7fc 100%);\">\n    \u003Ch2 class=\"aml-material-subtitle\">8. 漏服和过量怎么办❓\u003C/h2>\n    \u003Cul class=\"aml-material-list\">\n      \u003Cli>\n        \u003Cstrong>维奈克拉漏服：\u003C/strong>若记起时距下次服药不足8小时，直接跳过该剂量，勿双倍补服，继续后续给药。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>阿糖胞苷漏服：\u003C/strong>因为注射需专业人员操作，出现漏服应及时联系主诊医生，由专业团队重新安排方案。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>如不慎过量：\u003C/strong>维奈克拉或阿糖胞苷过量均属危急情况，应立刻送医院处理，不可自行处理。医院会根据具体情况实施洗胃、血液透析或特定解毒措施。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n  \n  \u003C!-- 数据与临床表现 -->\n  \u003Cdiv class=\"aml-material-section aml-material-bg\" style=\"background: linear-gradient(90deg, #f6f8ff 0%, #fff9fa 100%);\">\n    \u003Ch2 class=\"aml-material-subtitle\">9. 用药安全性与有效性数据📊\u003C/h2>\n    \u003Cul class=\"aml-material-list\">\n      \u003Cli>\n        \u003Cstrong>临床研究显示：\u003C/strong>联合维奈克拉和阿糖胞苷，完全缓解率达54.8%，并且患者白细胞计数下降更快，用药期间须加强监测（DiNardo et al., 2020）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>不良反应发生率：\u003C/strong>维奈克拉治疗相关毒性发生率为37%-47%，绝大多数在用药前期出现，早期监控尤其重要（Roberts et al., 2018）。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n  \n  \u003C!-- 综合小结与安全提醒 -->\n  \u003Cdiv class=\"aml-material-section aml-material-bg\" style=\"background: linear-gradient(90deg, #f1fbfc 0%, #fcf2e0 100%);\">\n    \u003Ch2 class=\"aml-material-subtitle\">10. 总结与安全用药提醒✅\u003C/h2>\n    \u003Cul class=\"aml-material-list\">\n      \u003Cli>\n        \u003Cspan>维奈克拉和阿糖胞苷具有鲜明的联合应用优势，关键是要掌握剂量递增、严格遵循专科指导，并做好禁忌药物、特殊群体、漏服过量等环节风险预防。\u003C/span>\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan>记住：所有治疗调整和不良反应处理都要在医生指导下进行。任何疑问随时咨询专科药师，绝不自行调整用药细节。\u003C/span>\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan>用药安全和疗效高效并重，只有尊重注意事项，才能让药品发挥最大作用。\u003C/span>\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\n  \u003C!-- 文献引用 -->\n  \u003Cdiv class=\"aml-material-section aml-material-reference\">\n    \u003Ch3 class=\"aml-material-ref-title\">引用文献📚\u003C/h3>\n    \u003Cul class=\"aml-material-list\">\n      \u003Cli>\n        Roberts, A. W., et al. (2018). Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. \u003Cem>New England Journal of Medicine\u003C/em>, 374(4), 311-322.\n      \u003C/li>\n      \u003Cli>\n        Döhner, H., et al. (2022). Diagnosis and management of acute myeloid leukemia in adults: 2022 recommendations from an international expert panel. \u003Cem>Blood\u003C/em>, 140(12), 1345-1377.\n      \u003C/li>\n      \u003Cli>\n        DiNardo, C. D., et al. (2020). Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. \u003Cem>Journal of Clinical Oncology\u003C/em>, 38(11), 1152-1161.\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.aml-material-root {\n  font-family: \"Helvetica Neue\", Helvetica, Arial, \"PingFang SC\", \"Microsoft YaHei\", SimHei, sans-serif;\n  color: #222;\n  background-color: #fff;\n  padding: 28px 18px 48px 18px;\n  max-width: 920px;\n  margin: 0 auto;\n  border-radius: 14px;\n  box-shadow: 0 2px 12px #eaf1fd;\n}\n.aml-material-title {\n  font-size: 36px;\n  line-height: 46px;\n  font-weight: 700;\n  letter-spacing: 1px;\n  margin-bottom: 28px;\n  text-align: center;\n  background: linear-gradient(90deg, #c8ebfc 20%, #fdf6dd 100%);\n  padding: 15px 12px 12px 12px;\n  border-radius: 10px;\n  color: #244d69;\n  box-shadow: 0 1px 5px #f3f0e8;\n}\n.aml-material-section {\n  margin-bottom: 38px;\n  padding: 0 16px 0 0;\n}\n.aml-material-section-intro p {\n  font-size: 20px;\n  background: linear-gradient(90deg, #f6fff2 0%, #f3fcfd 100%);\n  padding: 20px 18px 14px 18px;\n  border-radius: 8px;\n  color: #1483ab;\n  margin-bottom: 16px;\n  font-weight: 500;\n  box-shadow: 0 1px 2px #eef2f8;\n}\n\n.aml-material-bg {\n  border-radius: 12px;\n  padding: 24px 22px 16px 22px;\n  box-shadow: 0 2px 10px 0 #f2f4fa;\n}\n\n.aml-material-subtitle {\n  font-size: 26px;\n  font-weight: 600;\n  margin-bottom: 18px;\n  color: #317799;\n  letter-spacing: 0.02em;\n  padding-bottom: 5px;\n  border-bottom: 1px solid #e1ecf5;\n  background: linear-gradient(90deg,#f8fdfd 60%, #edf8fc 100%);\n  border-radius: 7px 7px 0 0;\n}\n\n.aml-material-list {\n  margin-top: 10px;\n  padding-left: 18px;\n}\n.aml-material-list li {\n  font-size: 18px;\n  margin-bottom: 10px;\n  padding-bottom: 4px;\n  line-height: 1.85;\n  color: #234d45;\n  background: transparent;\n  border-radius: 4px;\n}\n\n.aml-material-reference {\n  background: linear-gradient(90deg, #f2f8fb 40%, #fff7e6 100%);\n  padding: 22px 18px 14px 18px;\n  border-radius: 8px;\n  box-shadow: 0 1px 4px #e6eff9;\n}\n.aml-material-ref-title {\n  font-size: 22px;\n  font-weight: 600;\n  color: #5a7394;\n  margin-bottom: 12px;\n  padding-bottom: 4px;\n  border-bottom: 1px dashed #cfdef3;\n  background: linear-gradient(90deg,#ecf7fd 70%, #fbf6e7 100%);\n  border-radius: 5px 5px 0 0;\n}\n\n@media screen and (max-width: 700px) {\n  .aml-material-root {\n    padding: 10px 5px 16px 5px;\n    max-width: 99%;\n  }\n  .aml-material-title {\n    font-size: 24px;\n    line-height: 30px;\n    padding: 10px 7px 7px 7px;\n  }\n  .aml-material-section {\n    padding-right: 0;\n  }\n  .aml-material-reference {\n    padding: 10px 6px 7px 6px;\n  }\n}\n\u003C/style>","\u003C!-- 急性髓系白血病治疗指南：理解维奈克拉与阿糖胞苷的作用 -->\n\u003Cdiv class=\"aml-material-root\">\n  \u003Ch1 id=\"material_title\" class=","2025-10-30 00:19:32","急性髓系白血病, 维奈克拉, 阿糖胞苷, 药物相互作用, 化疗","掌握维奈克拉与阿糖胞苷的联合治疗优势，了解关键用药细节，提升急性髓系白血病患者治疗安全性与有效性，适合所有患者阅读。","2025-11-18 16:08:42",2,[33],{"menuId":34,"menuName":35,"parentId":21,"orderNum":31,"path":36,"component":37,"isFrame":38,"isCache":39,"menuType":40,"visible":41,"status":21,"createDept":6,"remark":23,"createTime":42,"children":43,"columnImage":44,"columnLogo":45,"uncheckedLogo":6,"checkedLogo":6,"isHot":41,"isHome":21,"forceLogin":21,"color":46,"seoTitle":47,"seoKeywords":48,"seoDescription":49,"contentNum":6,"promotionalPoster":50,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":51,"routerPath":36,"componentInfo":37},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":55,"success":53},{"pageNo":41,"pageSize":56,"result":57,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":59,"success":53},{"authors":60,"appraiseDimensionScoresVos":61},[],[]]